You are here

Press Release Archive

June 28, 2010 - Pfizer Invites Public To View And Listen To Webcast Of August 3 Conference Call With Analysts

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, August 3, 2010. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2010 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web

June 23, 2010 - Pfizer Declares An 18-Cent Third-Quarter 2010 Dividend

(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared an 18-cent third-quarter 2010 dividend on the company’s common stock, payable September 1, 2010, to shareholders of record at the close of business on August 6, 2010. The third-quarter 2010 cash dividend will be the 287th consecutive quarterly dividend paid by Pfizer.

June 22, 2010 - Pfizer Suspends Tanezumab Osteoarthritis Clinical Trial Program

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today the suspension of the osteoarthritis clinical program for the investigational compound tanezumab following a request by the U.S. Food and Drug Administration (FDA). The worldwide suspension – which is effective immediately – follows a small number of reports of tanezumab patients experiencing the worsening of osteoarthritis leading to joint replacement. To date, this adverse event has

June 20, 2010 - Pfizer Enters Into Agreement With Ergonex Pharma To Acquire Investigational Treatment For Pulmonary Arterial Hypertension

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Ergonex Pharma GmbH announced today that they have entered into an agreement under which Pfizer will acquire terguride, which is in development as a potential treatment for Pulmonary Arterial Hypertension (PAH). Under the terms of the agreement, Pfizer will support the completion of the ongoing Phase 2 trial for terguride and will have exclusive worldwide rights excluding Japan to commercialize

June 20, 2010 - Caduet Reduces 10-Year Calculated Risk Of Coronary Heart Disease, Fatal Cardiovascular Disease

(BUSINESS WIRE)--Caduet® (amlodipine besylate/atorvastatin calcium) was associated with a significantly reduced calculated 10-year risk of coronary heart disease (CHD) based on a Framingham risk assessment model. In addition, Caduet was shown to reduce calculated fatal cardiovascular disease (CVD) risk, as a secondary trial endpoint based on the SCORE risk assessment model. The Framingham and SCORE risk assessment models are widely used in the

June 16, 2010 - New CELEBREX® (celecoxib) Study Using Novel Endpoint, Published By The Lancet, Contributes to Knowledge Of NSAID-Associated Gastrointestinal Adverse Events

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced that new data, published today by The Lancet, show that arthritis patients at increased gastrointestinal (GI) risk taking CELEBREX demonstrated a significantly lower incidence of the novel composite endpoint of clinically significant upper and lower GI events compared with patients taking diclofenac plus omeprazole. This difference was driven by clinically significant decreases in hemoglobin

June 7, 2010 - Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Geno Germano, President and General Manager, Specialty Care & Vaccines, at the Goldman Sachs 31st Annual Global Healthcare Conference on Tuesday, June 15, 2010 at 8:35 a.m. Pacific Daylight Saving Time. To view and listen to the webcast, visit our web site at and click on the “Goldman Sachs

June 4, 2010 - Phase 3 Study Showed MACUGEN® Improved Vision Over Standard Of Care In Patients With Diabetic Macular Edema

(BUSINESS WIRE)--Results from a Phase 3 study demonstrate MACUGEN® (pegaptanib sodium) significantly improved vision in patients with diabetic macular edema (DME), a complication of diabetes that is a leading cause of blindness in people of working age.(1) In the study, 37 percent of patients treated with MACUGEN gained two lines, or 10 letters, of vision on the ETDRS eye chart at 54 weeks, compared to 20 percent of patients who received a

June 1, 2010 - Pfizer And Epocrates Partner To Give Healthcare Providers Access To Medical Information Specialists For Medication Questions

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Epocrates, Inc., today announced a collaboration to give healthcare providers (HCPs) mobile access to the Pfizer Medical Information Group to obtain scientific answers to their product questions or to report an adverse event. For the first time, clinicians can make direct contact through the Epocrates drug reference app on their iPhone® device to pharmaceutical manufacturers and immediately apply

May 26, 2010 - Pfizer Announces EMPHASIS-HF Trial To Halt Recruitment Due To Significant Benefit Observed In Patients Treated With Inspra® (Eplerenone)

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced that it plans to halt recruitment to the EMPHASIS-HF trial early on the recommendations of the trial’s independent Executive Steering Committee (ESC). The recommendations follow a second interim analysis by the independent Data Safety Monitoring Committee (DSMC) of the EMPHASIS-HF trial confirming the study has reached its primary efficacy endpoint early according to the protocol pre-defined

May 25, 2010 - Pfizer Appoints Mikael Dolsten President Of Worldwide Research And Development

(BUSINESS WIRE)--Today, Pfizer Inc. named Mikael Dolsten, M.D., PhD, President of Pfizer Worldwide Research and Development, as the Company completes its integration of these functions following the Wyeth acquisition. Dr. Dolsten previously led Wyeth’s Research and Development organization from May 2008, and after the close of the Wyeth acquisition was named President of Pfizer’s BioTherapeutics Research & Development. Prior to his

May 24, 2010 - Pfizer Animal Health Expands Global Commitment To A Safe Food Supply With A New Focus On Healthy Fish

(BUSINESS WIRE)--Pfizer Animal Health today announced its acquisition of Microtek International, Inc., a recognized innovator in aquaculture vaccines, R&D and healthcare diagnostic services. The acquisition further expands Pfizer’s commitment to a safe food supply from healthy beef and dairy cattle, swine, poultry and, now, fish. Total global fish production – largely for human consumption – now exceeds that of pork, poultry,

May 19, 2010 - Pfizer Oncology To Present New Clinical Data From Ten Molecules Across Multiple Tumor Types

(BUSINESS WIRE)--Pfizer Oncology will present new data highlighting the company’s focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology (ASCO) meeting in Chicago from June 4-8. “Pfizer Oncology is committed to applying discoveries from cancer biology and genetics to the development of new

May 18, 2010 - Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Jean-Michel Halfon, President and General Manager, Emerging Markets, at the Citi 2010 Global Healthcare Conference on Wednesday, May 26, 2010, at 10:30 a.m. Eastern Daylight Time. To view and listen to the webcast, visit our web site at and click on the “Citi 2010 Global HealthcarConference” link

May 18, 2010 - Pfizer Global Manufacturing Announces Plans To Reconfigure Its Global Plant Network

(BUSINESS WIRE)--Pfizer Global Manufacturing announced today plans to reconfigure its worldwide plant network to create a fully aligned manufacturing and supply organization from the combined networks of Pfizer and Wyeth. This implementation of the first phase of Pfizer’s previously announced Plant Network Strategy includes recommendations to cease operations at eight manufacturing sites in Ireland, Puerto Rico, and the United States by the

May 17, 2010 - Pfizer, Washington University Announce Groundbreaking Collaboration

(BUSINESS WIRE)--In a first-of-a-kind collaboration between academia and industry, Pfizer Inc. will give scientists at Washington University School of Medicine in St. Louis unprecedented access to information regarding more than 500 pharmaceuticals and pharmaceutical candidates in a partnership that focuses on discovering new uses for existing compounds. Under the five-year agreement announced today, Pfizer will provide $22.5 million

May 5, 2010 - Pfizer Animal Health Announces First Recipients of New $2 Million Veterinary Scholarship Program

(BUSINESS WIRE)--Pfizer Animal Health announced today the first recipients of a new $2 million scholarship program for U.S. veterinary students. The initiative, designed to support the future of the veterinary profession, will provide up to $2 million in scholarships over its first three years. Administered in partnership with the American Veterinary Medical Foundation (AVMF), the program is an opportunity for Pfizer Animal Health to

May 3, 2010 - Pfizer Reports First-Quarter 2010 Results; Reaffirms 2010 Financial Guidance

BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE): First-Quarter 2010 Revenues of $16.8 Billion First-Quarter 2010 Reported Diluted EPS(1) of $0.25, Adjusted Diluted EPS(2) of $0.60 Reaffirms 2010 Financial Guidance and 2012 Diluted EPS Target Ranges Continues to Make Solid Progress on the Wyeth Integration ($ in millions, except per share

April 23, 2010 - World Bank And Pfizer Announce Initiative To Help Improve Healthcare Delivery In Developing Countries



Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.


Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.


If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.